On Wegovy, users can expect to lose an average of 14% to 19% of starting body weight gradually over 64 to 72 weeks
Moderate side effects may include constipation or diarrhea, upset stomach, nausea or vomiting, headaches, abdominal pain, fatigue, and low blood sugar
Whether retatrutide will offer meaningful advantages for people with metabolic dysfunction-associated steatotic liver disease (MASLD) remains to be confirmed in Phase 3 trials
This dual action is the leading reason tirzepatide has tended to produce greater average weight loss in studies, though both are effective and the right choice depends on the individual
Khatibi PA, et al
Our approach to hormone replacement therapy in Greeley is designed for those who expect moremore energy, sharper focus, and a body that can keep up with the demands of life